Research programme: protease inhibitors - Consensus/Vertex
Latest Information Update: 01 May 2007
At a glance
- Originator Consensus Pharmaceuticals; Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 01 May 2007 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 13 Jul 2001 Preclinical development for Undefined in USA (unspecified route)